Laboratorios Farmaceuticos Rovi, S.A.
ROVI
शेयरों में रैंक
#4484
Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that focuses... Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that focuses on researching, developing, manufacturing, and commercializing medicinal products. Its operations span Spain, the European Union, OECD nations, and global markets. The company also markets certain products under license from other manufacturers. Its primary pharmaceutical portfolio includes Hibor and Enoxaparin biosimilar Becat, both low-molecular-weight heparins for preventing and treating venous thromboembolic conditions. Neparvis targets symptomatic chronic heart failure with reduced ejection in adult patients. For managing hypercholesterolemia, Rovi offers Absorcol, Vytorin, and Orvatez. Respiratory diseases like chronic obstructive pulmonary disease are treated with long-acting bronchodilators Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is available for men with benign prostatic hyperplasia (BPH) experiencing moderate to severe storage and voiding symptoms who have not adequately responded to monotherapy. Additionally, Medikinet and Medicebrán are used for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent patients. Beyond pharmaceuticals, Rovi provides various hospital solutions for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventions, Multihance and Prohance for MRI, and Sonovue for ultrasounds. It also supplies contrast injection systems such as EmpowerCTA+, EmpowerMR, and CT Exprès, along with compatible disposable materials. The company's offerings extend to over-the-counter pharmaceuticals and contract manufacturing services for other firms, producing a range of dosage forms like prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi serves a broad client base, including pharmaceutical wholesalers, medical professionals, nurses, pharmacists, and individual patients. Notably, Rovi has partnered with Moderna, Inc. for the production of an mRNA COVID-19 vaccine candidate. Established in 1946, the company is headquartered in Madrid, Spain, and operates as a subsidiary of Norbel Inversiones, S.L.
शेयर मूल्य
$66.37
मार्केट कैप
$3.39B
बदलाव (1 दिन)
0.42%
बदलाव (1 वर्ष)
-11.18%
देश
ES
व्यापार Laboratorios Farmaceuticos Rovi, S.A. (ROVI)
श्रेणी
Healthcare
Laboratorios Farmaceuticos Rovi, S.A. (ROVI) के लिए बकाया शेयरों की संख्या
October 2026 की स्थिति में बकाया शेयरों की संख्या: 0
Laboratorios Farmaceuticos Rovi, S.A. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी के वर्तमान बकाया शेयरों की संख्या 0 है। October 2026 के अंत में कंपनी के पास 0 बकाया शेयर थे। बकाया शेयरों की संख्या आमतौर पर शेयर स्प्लिट्स और शेयर बायबैक से प्रभावित होती है।
Laboratorios Farmaceuticos Rovi, S.A. (ROVI) के लिए 2004 से 2026 तक बकाया शेयरों का इतिहास
प्रत्येक वर्ष के अंत में बकाया शेयर
| वर्ष | बकाया शेयर | परिवर्तन |
|---|---|---|
| 2025 | 51.15M | -0.23% |
| 2024 | 51.27M | -1.07% |
| 2023 | 51.82M | -3.08% |
| 2022 | 53.47M | -3.50% |
| 2021 | 55.40M | 0.03% |
| 2020 | 55.39M | 0.37% |
| 2019 | 55.18M | 7.73% |
| 2018 | 51.22M | 3.88% |
| 2017 | 49.31M | 0.56% |
| 2016 | 49.03M | -1.02% |
| 2015 | 49.54M | -0.43% |
| 2014 | 49.75M | -0.12% |
| 2013 | 49.81M | 0.31% |
| 2012 | 49.66M | -0.06% |
| 2011 | 49.69M | -0.09% |
| 2010 | 49.73M | -0.54% |
| 2009 | 50.00M | 0.00% |
| 2008 | 50.00M | 0.00% |
| 2007 | 50.00M | 0.00% |
| 2006 | 50.00M | 0.00% |
| 2005 | 50.00M | 0.00% |
| 2004 | 50.00M | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए बकाया शेयर
| कंपनी | बकाया शेयर | अंतर | देश |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | - |
IN
|
